 |
|
|
 |
1-Hydroxypyrene
| Scope & Reporting Limit |
1-Hydroxypyrene 0.4 ng/mL urine |
| Acode |
2358U (Urine) |
| Method of Analysis |
High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS) |
| Specimen Requirements |
4 mL Urine. Transport Temperature:Frozen. Specimens must be maintained frozen since 1-Hydroxypyrene is not stable. Specimens received room temperature or refrigerated will be rejected. |
|
Tramadol Screen
| Scope & Reporting Limit |
Tramadol: 150 ng/mL urine |
| Acode |
9287U (Urine) |
| Method of Analysis |
Immunoassay (IA) |
| Specimen Requirements |
2 mL Urine |
| Pharmacokinetics |
Approximately 30% of a dose is excreted as unchanged Tramadol in the urine. |
Meperidine Screen
| Scope & Reporting Limit |
Meperidine: 0.20 mcg/mL |
| Acode |
9444U (Urine) |
| Method of Analysis |
Immunoassay (IA) |
| Reporting Limit |
Meperidine: 0.20 mcg/mL |
| Specimen Requirements |
4 mL Urine |
Hypoglycemic Panel
| Scope & Reporting Limit |
Acetohexamide (Dymelor®): 300 ng/mL
Chlorpropamide (Diabinese®): 300 ng/mL
Glimepiride (Amaryl®): 5 ng/mL
Glipizide (Glucotrol®): 5 ng/mL
Glyburide (Micronase®): 5 ng/mL
Nateglinide (Starlix®): 50 ng/mL
Repaglinide (Prandin®): 10 ng/mL
Tolazamide (Tolinase®): 300 ng/mL
Tolbutamide (Orinase®): 300 ng/mL |
| Acode |
4261B (Blood), 4261SP (Serum/Plasma)
Urine is not an acceptable matrix |
| Method of Analysis |
High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS) |
| Specimen Requirements |
1 mL of Blood, Serum or Plasma
The use of serum separator tubes is not acceptable.
Submission of a serum separator tube will result in cancellation. |
| Stability |
Ambient: 7 days
Refrigerated: 14 days
Frozen (-20 C): 14 days |
Eszopiclone/Zopiclone
| Scope & Reporting Limit |
Eszopiclone /Zopiclone
2.0 ng/mL Blood, Serum, Plasma, or Urine |
| Acode |
1968B (Blood)
1968SP (Serum/Plasma)
1968U (Urine) |
| Method of Analysis |
High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS) |
| Specimen Requirements |
1 mL Serum, Plasma, Blood or Urine. Freeze and ship frozen. Analysis of tissue samples also available. Contact lab for more information.
The use of serum separator tubes is not acceptable. |
|
|
| Special Handling |
Specimens must be maintained frozen since Eszopiclone / Zopiclone is not stable. |
| Pharmacokinetics |
This test is not Chiral specific. Patients who have taken racemic Zopiclone (not approved in the US), as opposed to Eszopiclone (Lunesta®), within the past day may have falsely elevated values.
A single 3 mg Eszopiclone oral dose produced peak serum concentrations of 20 to 30 ng/mL within 2 hours.
Once daily 2 mg Eszopiclone oral doses given to elderly adults for 7 days resulted in a peak serum concentration of approximately 15 ng/mL. |
Depleted Uranium
| Acode |
9230U (Urine) Uranium, Total and Depleted Screen |
| Scope & Reporting Limit |
Depleted Uranium
0.10 mcg/L |
| Method of Analysis |
Inductively Coupled Plasma/Mass Spectrometry (ICP/MS) |
| Specimen Requirements |
10 mL Urine |
| Reporting Comment |
U235 percentage in individuals exposed to depleted Uranium is in the range of 0.20% - 0.33% of total Uranium. |
|
Uranium. Agency for Toxic Substances and Disease Registry. www.atsdr.cdc.gov/. September 1999.
|
Tizanidine
| Acodes |
4487B (Blood) and 4487SP (Serum/Plasma) |
| Scope & Reporting Limit |
Tizanidine (Zanaflex®)
0.2 ng/mL |
| Method of Analysis |
Liquid Chromatography/ Tandem Mass Spectrometry (LC/MS/MS) |
| Specimen Requirements |
1 mL Serum, Plasma, or Blood.
The use of serum separator tubes is not recommended. |
| Pharmacokinetics |
Based on a few human pharmacokinetic studies, the following therapeutic data was reported:
1Cmax (mean ±S.D.)= 25.8 ± 8.5 ng/mL at 1.3 hrs. (Single 8 mg oral dose)
2Cmax (mean ±S.D.)= 3.1 ± 1.3 ng/mL at 1.0 hr., decreasing to less than 1 ng/mL after 6 hrs. (Single 5 mg oral dose)
3Cmax (mean ±S.D.)= 2.5 ± 1.1 ng/mL at 0.9 hours after the last dose (Chronic 4 mg orally q 8 hrs. for 7 days) |
| References |
Based on a few human pharmacokinetic studies, the following therapeutic data was reported:
1Mathias, C.J., J. Luckwitt, D. Pankaj, H. Baker, W.E. Masri and H.L. Frankel (1989): "Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury," J. Rehab. Res. 26: 9-16.
2Tse, F.L.S., J.M. Jaffe, and S. Bhuta (1987): "Pharmacokinetics of orally administrated tizanidine in healthy volunteers," Fundam. Clin. Pharmacol. 1:479-488.
3Shellenberger, M.K., L. Groves, J. Shah and G.D. Novack (1999): "A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state," Drug Metab. Disp. 27: 201-204. |
|
|
|
|